Publication | Open Access
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α–Based Regimens
92
Citations
39
References
2013
Year
Rbv TherapyImmunodeficienciesGenetic EpidemiologyImmunologyPharmacotherapyAntiviral DrugImmunotherapyImmune-related Gene PolymorphismGenetic MedicineImmunogeneticsPeg Interferon-α–based RegimensViral HepatitisAntiviral Drug DevelopmentClinical TrialsPharmacogenomicsPeg-ifn 2AVirologyChronic Viral InfectionPharmacologyInborn Error Of ImmunityMolecular MedicineGene TherapiesHepatologyHepatitis CIfnl3 GenotypeHepatitisAntiviral TherapyMedical GeneticsMedicineViral Immunity
Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.
| Year | Citations | |
|---|---|---|
Page 1
Page 1